Max Rosett - 15 Jun 2026 Form 4 Insider Report for Immunome Inc. (IMNM)

Reporting relationship: Chief Financial Officer
Issuer ticker: IMNM
Reported as of: 15 Jun 2026
Net transaction value: -$1,093,800
SEC form: 4
Accepted by SEC: 17 Jun 2026, 17:26:19 UTC
Prior SEC filing: 03 Apr 2026
Next SEC filing: 27 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Sandra Stoneman, Attorney-in-Fact

Key filing fact

Max Rosett filed Form 4 for Immunome Inc. (IMNM) on 17 Jun 2026.

Key facts

This page summarizes Max Rosett's Form 4 filing for Immunome Inc. (IMNM).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 17:26.

Change

Previous filing in this sequence was filed on 03 Apr 2026.
Current net transaction value: -$1,093,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001994071 Primary reporting owner

Rosett Max

Relationship: Chief Financial Officer
Address: C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL
Signature: /s/ Sandra Stoneman, Attorney-in-Fact
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNM transaction

Common Stock

Options Exercise

Transaction value
Shares: +60,000
Change %: +111%
Price: $1.05^*
Shares after: 114,037
Date: 15 Jun 2026
Ownership: Direct

IMNM transaction

Common Stock

Sale

Transaction value: $1,093,800
Shares: -60,000
Change %: -53%
Price: $18.23
Shares after: 54,037
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNM transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -60,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $1.05
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

Footnote F2

The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

Footnote F3

The option is fully vested.